Overcoming Hindrances to Merah Putih Vaccine Research
Of the six Merah Putih candidate vaccines being developed in the country, the vaccine from Uniair and PT Biotis has shown the most progress.
/https%3A%2F%2Fkompas.id%2Fwp-content%2Fuploads%2F2021%2F02%2F20210225RAD07_1614348770.jpg)
A health worker prepares vaccines during the mass Covid-19 vaccination for media workers at Basket Hall, Bung Karno Stadium complex, Senayan, Jakarta, on Thursday (25/2/2021). On the first day of the vaccination, the event was attended by over 1,000 media workers from various press companies. The mass vaccination for media will run until Saturday (27/2/2021), targeting 5,500 media workers. The Covid-19 vaccine is expected to protect the media workers from risk of Covid-19 transmission.
The limited availability of experts and infrastructure both hamper COVID-19 vaccine development. This issue must be addressed thoroughly so that Indonesia can begin producing its own vaccine.
JAKARTA, KOMPAS — The limited number of human resources and research infrastructure have not dampened the enthusiasm of Indonesian COVID-19 vaccine researchers, as domestic vaccine development must be realized.
Versi cetak artikel ini terbit di harian Kompas edisi di halaman 1 dengan judul "Atasi Kendala Riset Vaksin Merah Putih".
Baca Epaper Kompas